Clinical trials: Stable Schizophrenia
Schizophrenia
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms (such as blunted affect, emotional withdrawal, and poor rapport) of schizophrenia.
- Trial name
- NCT00212836
- Testing
- asenapine, olanzapine
- Volunteers
- 481 people
- Sponsor
- Organon and Co
Schizophrenia
A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers
The purpose of this study is to measure and contrast implicit and explicit learning performance in patients with schizophrenia relative to young and elderly healthy volunteers.
- Trial name
- NCT01788436
- Testing
- Cognitive Test Battery 1, Cognitive Test Battery 2
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics (explores what the body does to the drug) of JNJ-37822681 in participants with stable schizophrenia (psychiatric disorder with symptoms of…
- Trial name
- NCT01812642
- Testing
- JNJ-37822681
- Where
- 6 sites in Belgium, Germany and 3 more
- Volunteers
- 33 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03004 following an escalating single intramuscular injection at 12.5, 25, 37.5, or 50 mg; and to evaluate the safety and tolerability and preliminary…
- Trial name
- LY03004SAD (NCT02055287)
- Testing
- LY03004
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Schizo-affective Disorder
Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF-02545920 subjects with schizophrenia or schizo-affective disorder who are currently clinically stable and to evaluate the serum and urine pharmacokinetics of…
- Trial name
- NCT00463372
- Testing
- PF-02545920
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- Pfizer
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308 administered for 14 days in subjects with…
- Trial name
- NCT02037074
- Testing
- Drug: EVP-6308
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo
This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with non-active treatment.
- Trial name
- NCT00228462
- Testing
- Seroquel (quetiapine)
- Where
- 5 sites in Bulgaria, Poland
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Schizophrenia
A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.
The purpose of this study is to compare the pharmacokinetics and safety of long-acting injectable risperidone, an atypical antipsychotic medication used for the treatment of patients with schizophrenia, when it is administered as…
- Trial name
- NCT00843687
- Testing
- Risperidone long-acting injectable
- Volunteers
- 188 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Bioavailability of LY03004 and Risperdal® Consta®
This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections
- Trial name
- NCT02091388
- Testing
- LY03004, Risperdal® Consta®
- Where
- 10 sites in United States
- Volunteers
- 108 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
- Trial name
- NCT01900522
- Testing
- ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
This is an Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114).
- Trial name
- DLP-114 (NCT04418466)
- Testing
- Risperidone
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Delpor, Inc.
Schizophrenia
Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients
Approximately 30-60% of all schizophrenia patients who fail to respond to typical antipsychotics may respond to Clozapine. Clozapine has long been considered the "gold standard" within the atypical neuroleptic spectrum, backed by…
- Trial name
- NCT01663077
- Testing
- Clozapine
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Tirat Carmel Mental Health Center
Schizophrenia
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms (such as blunted affect, emotional withdrawal, and poor rapport) of schizophrenia.
- Trial name
- NCT00145496
- Testing
- Asenapine, Olanzapine
- Volunteers
- 468 people
- Sponsor
- Organon and Co
Schizophrenia
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
- Trial name
- NCT01760889
- Testing
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg)
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Shire
Schizophrenia
Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
This is a multiple ascending dose study; the purpose of this study is to examine the safety, tolerability and pharmacokinetics (levels of drug in the blood) of SPD489 in Schizophrenic Patients who are currently maintained on a…
- Trial name
- NCT01457339
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Shire
Bipolar Disorder, Schizophrenia
A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)
The basic hypothesis of this trial is that forgetfulness and failure to establish a routine that facilitates medication adherence are prominent reasons for non-adherence.
- Trial name
- SEQUEL (NCT00533260)
- Where
- 35 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- AstraZeneca